Top Markets
Coin of the day
InnoPharmax Inc. InnoPharmax Inc.

InnoPharmax Inc.

4172
Rang in Aktien #26286
InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan,... InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan, operates as a specialized pharmaceutical enterprise. The company's core activities revolve around the development and market introduction of therapeutic products, with a particular focus on oncology and various other specialized medical fields within the Taiwanese market. Their current commercial portfolio encompasses N11005, an oral insulin designed for administration with meals, alongside GemOral. They also provide an Imipenem and Cilastatin solution, utilized for treating a broad spectrum of bacterial infections affecting areas such as the lower respiratory tract, skin and soft tissue, internal abdominal organs, gynecological systems, and bone and joints. Furthermore, InnoPharmax offers contrast agents, specifically gadopentetate dimeglumine and gadodiamide; oncology medications like Innomustine and Immurin; and Inpheno tablets, which are indicated for rare diseases. The company also provides advanced technology platforms, including the MUCR system, OralPas, and OralPas Pro. Looking at its research and development pipeline, InnoPharmax has several promising candidates. D07001 is currently in Phase I clinical trials for tumor treatment. C08001 has progressed to Phase III, targeting hypertension, heart failure, and left ventricular dysfunction following a myocardial infarction. Additional compounds in pilot bioequivalence (BE) trials include D07002, a potential supplement for phenylketonuria; C07001 for the management of Parkinson's disease; and N11001, which is being investigated for urological applications. The company is also actively formulating new contrast agents, D0131502 and D0051301.
Aktienkurs
$0.35614911
Marktkapitalisierung
$41.95M
Veränderung (1 Tag)
0.45%
Veränderung (1 Jahr)
-50.84%
Land
TW
Handel InnoPharmax Inc. (4172)

Kategorie

Preis 4172 mit Marktkapitalisierung von B
InnoPharmax Inc. InnoPharmax Inc.
4172
$0.35614911
Marktkapitalisierung von InnoPharmax Inc.(4172)
Marktkapitalisierung: $41.95M
Mit Stand August 2026 hat InnoPharmax Inc. eine Marktkapitalisierung von $41.95M. Das macht InnoPharmax Inc. laut unseren Daten zum 26286th wertvollsten Unternehmen der Welt nach Marktkapitalisierung. Die Marktkapitalisierung ist der Gesamtmarktwert aller ausstehenden Aktien eines börsennotierten Unternehmens und wird häufig verwendet, um den Unternehmenswert zu bestimmen.
Marktkapitalisierung von InnoPharmax Inc. von 2012 bis 2026
4172 im Vergleich zu den Top 5 der beliebtesten stocks
Preis für 4172 Vermögenswert B Marktkapitalisierung von B Ergebnisse
InnoPharmax Inc. InnoPharmax Inc.
$44,601.60 $41.95M
$5.253T +12,523,194.22%
InnoPharmax Inc. InnoPharmax Inc.
$39,553.91 $41.95M
$4.658T +11,105,897.55%
InnoPharmax Inc. InnoPharmax Inc.
$34,820.33 $41.95M
$4.101T +9,776,795.95%
InnoPharmax Inc. InnoPharmax Inc.
$30,489.99 $41.95M
$3.591T +8,560,918.75%
InnoPharmax Inc. InnoPharmax Inc.
$24,038.73 $41.95M
$2.831T +6,749,524.52%